- Home
- PRQR vs FLC Comparison
PRQR vs FLC Comparison
Compare PRQR & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRQR | FLC |
|---|---|---|
| Founded | 2012 | N/A |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.5M | 179.0M |
| IPO Year | 2014 | 2003 |
Fundamental Metrics
Financial Performance| Metric | PRQR | FLC |
|---|---|---|
| Price | $1.53 | $16.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.25 | N/A |
| AVG Volume (30 Days) | ★ 710.7K | 25.0K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.92 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $16.26 |
| 52 Week High | $3.10 | $18.09 |
Technical Indicators
Market Signals| Indicator | PRQR | FLC |
|---|---|---|
| Relative Strength Index (RSI) | 42.73 | 34.25 |
| Support Level | $1.51 | $16.26 |
| Resistance Level | $1.58 | $17.38 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 31.67 | 60.38 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.